Neulasta Solution For Injection 6Mg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • myWeekly Ad

Neulasta: Solution for injection (6mg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file default-drug-image.png
Neulasta 6mg/0.6ml Sol for Inj

What is this Medicine?

PEGFILGRASTIM (peg fil GRA stim) is a long-acting granulocyte colony-stimulating factor that stimulates the growth of neutrophils, a type of white blood cell important in the body's fight against infection. It is used to reduce the incidence of fever and infection in patients with certain types of cancer who are receiving chemotherapy that affects the bone marrow.

CVS Pharmacy Patient Statistics for Neulasta: Solution for injection(6mg)
Generic vs. Brand Name Usage*
*Brand contains same active ingredient but may not represent FDA-approved generic equivalent
Usage By Strength
In-Depth Information

Neulasta 6mg/0.6ml Solution for Injection

NDC: 555130190
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Chemotherapy-induced Neutropenia, Radiation Exposure

Storage Information
Refrigerate (between 36 and 46 degrees F)
Protect from light
Product should not be stored at room temperature for more than 48 hours
Store in carton
Protect from freezing
Neulasta 6mg/0.6ml Solution for Injection

Reported Side Effects for Neulasta 6mg/0.6ml Solution for Injection

Removal Of Spleen Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Splenic Rupture Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Glomerulonephritis Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Antibody Formation Incidence:
<6.0%*
Severity: MODERATE
Onset: DELAYED
Blood Vessel Fluid Leak Incidence:
<1.0%*
Severity: SEVERE
Onset: EARLY
High White Blood Cells Incidence:
<1.0%*
Severity: MILD
Onset: DELAYED
Acute Lung Injury Incidence:
<1.0%*
Severity: SEVERE
Onset: EARLY
Bone Pain Incidence:
31.0%*
Severity: MODERATE
Onset: DELAYED
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Pregnancy & Lactation Information
FIRST Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

SECOND Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

THIRD Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

Lactation

Caution - Not enough information is available to rule out harm to infants when this drug is taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Neulasta

Be the first to share your experience!

We want to help our customers stay educated about the medications they are taking. Submit your own observations and experiences to benefit others.

Average Scores
Easy to Take 
0 / 5
0 / 5
Works as Intended 
0 / 5
0 / 5
Tolerable 
0 / 5
0 / 5